Submissions on access to therapies  

Prescribed drugs, medical devices, and nutritional supplements are critical to the health and well-being of people with cystic fibrosis. Cystic Fibrosis Canada makes representations to governments on issues concerning access to life-sustaining therapies that improve the quality and length of life of Canadians living with the disease.

• Letter to the Provincial Ministers of Health regarding the reimbursement of Hyper-Sal 7% [New Brunswick] - March 27, 2012
   
• Submission on TOBI Podhaler® to the Drug Advisory Committee of Saskatchewan - January 23, 2012
   
• Submission to the Atlantic Common Drug Review for TOBI^® and TOBI Podhaler^® – November 18, 2011 
    
• Letter to the Natural Health Product Directorate, Health Canada, on Hyper-Sal 7% - October 28, 2011
   
• Submission of Patient Evidence for TOBI Podhaler^® to the Ontario Ministry of Health and Long-term Care – September 30, 2011
   
• Patient Input Submission on Cayston® to the Common Drug Review – December 21, 2010
   

Reviewed/updated: 2012-04-13